Adaptimmune Therapeutics PLC — Director's Dealing 2019

Aug 6, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-08-01

Reporting Person: Lunger John (Chief Patient Supply Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	28806	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$0.92	2027-04-03	Ordinary Shares (250032)		Direct
Option to purchase Ordinary Shares	$0.81	2027-07-07	Ordinary Shares (300000)		Direct
Option to purchase Ordinary Shares	$1.30	2028-01-12	Ordinary Shares (100800)		Direct
Option to purchase Ordinary Shares	$0.0014		Ordinary Shares (50850)		Direct
Option to purchase Ordinary Shares	$1.98	2028-07-02	Ordinary Shares (181872)		Direct
Option to purchase Ordinary Shares	$0.0013		Ordinary Shares (91386)		Direct
Option to purchase Ordinary Shares	$0.89	2029-01-04	Ordinary Shares (100800)		Direct
Option to purchase Ordinary Shares	$0.0013		Ordinary Shares (67800)		Direct

Footnotes

F1: Represented by 4,801 American Depositary Shares ("ADS") held by Mr. Lunger. Mr. Lunger holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer.

F2: Exercisable as to 62,508 Ordinary Shares on April 3, 2018 and will be exercisable as to the remainder in monthly installments of 5,209 Ordinary Shares on the third of each month from May 3, 2018 through April 3, 2021.

F3: The exercise price was converted from GBP0.74 based on an exchange rate of U.S.$1.2493 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 75,000 Ordinary Shares on July 7, 2018 and will be exercisable as to the remainder in monthly installments of 6,250 Ordinary Shares on the seventh of each month from August 7, 2018 through July 7, 2021.

F5: The exercise price was converted from GBP0.62 based on an exchange rate of U.S.$1.2949 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F6: Exercisable as to 25,200 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 2,100 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.

F7: The exercise price was converted from GBP0.96 based on an exchange rate of U.S.$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F8: Exercisable as to 16,950 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 16,950 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.

F9: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

F10: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F11: Exercisable as to 45,468 Ordinary Shares on July 2, 2019 and will be exercisable as to the remainder in monthly installments of 3,789 Ordinary Shares on the second of each month from August 2, 2019 through July 2, 2022.

F12: The exercise price was converted from GBP1.50 based on an exchange rate of U.S.$1.3196 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F13: Exercisable as to 30,462 Ordinary Shares on July 2, 2019 and will be exercisable as to the remainder in annual installments of 30,462 Ordinary Shares on the second of each July from July 2, 2020 through July 2, 2022.

F14: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

F15: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.3196 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F16: Exercisable as to 25,200 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 2,100 Ordinary Shares on the fourth of each month from February 4, 2020 through January 4, 2023.

F17: The exercise price was converted from GBP0.70. based on an exchange rate of U.S.$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F18: Exercisable as to 16,950 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 16,950 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023.

F19: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

F20: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.